Used in research and development for Alzheimer’s disease, this antibody targets amyloid-beta plaques in the brain, helping to clear pathological protein aggregates associated with disease progression. It serves as a reference standard in immunoassays, binding studies, and imaging applications to evaluate amyloid burden and therapeutic efficacy. Commonly employed in preclinical and clinical settings to support the development of diagnostics and immunotherapies aimed at modifying Alzheimer’s pathology.